Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) had its price objective increased by Cantor Fitzgerald from $24.00 to $34.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 202.90% from the company’s current price.
Several other equities research analysts also recently issued reports on the stock. Weiss Ratings downgraded shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. BTIG Research began coverage on shares of Zevra Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $23.00 price target for the company. Guggenheim boosted their price objective on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, Wall Street Zen lowered shares of Zevra Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $25.00.
Get Our Latest Research Report on Zevra Therapeutics
Zevra Therapeutics Stock Performance
Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.12. The business had revenue of $36.22 million during the quarter, compared to analysts’ expectations of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%. As a group, analysts anticipate that Zevra Therapeutics will post 0.56 EPS for the current year.
Hedge Funds Weigh In On Zevra Therapeutics
Hedge funds have recently made changes to their positions in the business. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in shares of Zevra Therapeutics during the 4th quarter worth about $53,000. Russell Investments Group Ltd. increased its stake in Zevra Therapeutics by 235.7% in the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after acquiring an additional 4,475 shares during the period. Tower Research Capital LLC TRC raised its position in Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after purchasing an additional 8,552 shares in the last quarter. Creative Planning bought a new position in Zevra Therapeutics during the second quarter worth about $92,000. Finally, Qube Research & Technologies Ltd bought a new position in Zevra Therapeutics during the second quarter worth about $99,000. Institutional investors and hedge funds own 35.03% of the company’s stock.
About Zevra Therapeutics
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.
Featured Stories
- Five stocks we like better than Zevra Therapeutics
- What’s Make of Macy’s: Berkshire Hathaway’s Latest Buy
- Planet Labs: Coming Back Down to Earth
- Docusign: Another Beat, Another Selloff—Why the Analysts Are Wrong
- Meta Unveils Subscriptions: A New Offering With Real Growth Potential
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
